- Home
- PLG vs PRLD Comparison
PLG vs PRLD Comparison
Compare PLG & PRLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PLG | PRLD |
|---|---|---|
| Founded | 2000 | 2016 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Medicinal Chemicals and Botanical Products |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 223.4M | 218.0M |
| IPO Year | 2002 | 2020 |
Fundamental Metrics
Financial Performance| Metric | PLG | PRLD |
|---|---|---|
| Price | $1.77 | $4.65 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $5.67 |
| AVG Volume (30 Days) | ★ 1.3M | 459.5K |
| Earning Date | 04-10-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 23.21 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $12,140,000.00 |
| Revenue This Year | N/A | $320.10 |
| Revenue Next Year | N/A | $100.00 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 73.43 |
| 52 Week Low | $1.10 | $0.73 |
| 52 Week High | $4.04 | $5.54 |
Technical Indicators
Market Signals| Indicator | PLG | PRLD |
|---|---|---|
| Relative Strength Index (RSI) | 45.06 | 57.87 |
| Support Level | $1.39 | $1.17 |
| Resistance Level | $2.01 | $5.54 |
| Average True Range (ATR) | 0.08 | 0.67 |
| MACD | 0.00 | -0.01 |
| Stochastic Oscillator | 32.39 | 53.94 |
Price Performance
Historical ComparisonAbout PLG Platinum Group Metals Ltd. (Canada)
Platinum Group Metals Ltd is a development-stage company, conducts work on mineral properties it has staked or acquired by way of option agreements in the Republic of South Africa. Key metals of economic interest on the company's mineral properties include platinum, palladium, rhodium, gold, copper, and nickel. The company operates in one segment, the development of the Waterberg Project in South Africa, and geographically in Canada and South Africa.
About PRLD Prelude Therapeutics Incorporated
Prelude Therapeutics Incorp is a precision oncology company developing medicines in areas of high unmet need for cancer patients. Its pipeline features selective KAT6A degraders and mutant selective JAK2V617F JH2 inhibitors, new approaches to clinically validated targets with transformative potential for patients. The company is also leveraging its expertise in targeted protein degradation to discover and develop next-generation degrader antibody conjugates (DACs) with novel payloads.